Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Indivior PLC (NASDAQ/LSE: INDV) has acknowledged a letter published by Oaktree Capital Management to its Board of Directors. The Board confirms it has been actively engaging with Oaktree in recent weeks and maintains an open-minded stance regarding proposals for value creation. Indivior, a global pharmaceutical company focused on substance use disorders (SUD) treatment, emphasizes its commitment to acting in the best interests of all shareholders while executing its strategy. The company operates in over 30 countries and employs more than 1,000 people globally.
Indivior PLC (NASDAQ/LSE: INDV) ha preso atto di una lettera pubblicata da Oaktree Capital Management al suo Consiglio di Amministrazione. Il Consiglio conferma di aver avuto contatti attivi con Oaktree nelle ultime settimane e mantiene un atteggiamento aperto nei confronti delle proposte per la creazione di valore. Indivior, una compagnia farmaceutica globale focalizzata nel trattamento dei disturbi da uso di sostanze (SUD), sottolinea il suo impegno a operare nel miglior interesse di tutti gli azionisti mentre attua la sua strategia. L'azienda opera in oltre 30 paesi e impiega più di 1.000 persone a livello globale.
Indivior PLC (NASDAQ/LSE: INDV) ha reconocido una carta publicada por Oaktree Capital Management a su Directorio. El Directorio confirma que ha estado en contacto activo con Oaktree en las últimas semanas y mantiene una postura abierta respecto a las propuestas para la creación de valor. Indivior, una compañía farmacéutica global enfocada en el tratamiento de trastornos por uso de sustancias (SUD), enfatiza su compromiso de actuar en el mejor interés de todos los accionistas mientras ejecuta su estrategia. La compañía opera en más de 30 países y emplea a más de 1,000 personas a nivel mundial.
인디비어 PLC (NASDAQ/LSE: INDV)는 오크트리 캐피탈 매니지먼트가 이사회에 발표한 서신을 확인하였습니다. 이사회는 최근 몇 주간 오크트리와 활발히 소통해 왔으며, 가치 창출에 대한 제안에 대해 열린 자세를 유지하고 있음을 확인합니다. 인디비어는 물질 사용 장애(SUD) 치료에 중점을 둔 글로벌 제약 회사로, 모든 주주의 이익을 최우선으로 삼아 전략을 실행하겠다는 의지를 강조합니다. 이 회사는 30개 이상의 국가에서 운영되며, 전 세계적으로 1,000명 이상의 직원을 고용하고 있습니다.
Indivior PLC (NASDAQ/LSE: INDV) a pris note d'une lettre publiée par Oaktree Capital Management à son conseil d'administration. Le conseil confirme qu'il a été en contact actif avec Oaktree ces dernières semaines et adopte une attitude ouverte concernant les propositions de création de valeur. Indivior, une entreprise pharmaceutique mondiale axée sur le traitement des troubles liés à l'usage de substances (SUD), souligne son engagement à agir dans le meilleur intérêt de tous les actionnaires tout en exécutant sa stratégie. L'entreprise opère dans plus de 30 pays et emploie plus de 1 000 personnes à l'échelle mondiale.
Indivior PLC (NASDAQ/LSE: INDV) hat ein Schreiben von Oaktree Capital Management an seinen Vorstand anerkannt. Der Vorstand bestätigt, dass er in den letzten Wochen aktiv mit Oaktree im Gespräch war und eine aufgeschlossene Haltung gegenüber Vorschlägen zur Wertschöpfung beibehält. Indivior, ein globales Pharmaunternehmen, das sich auf die Behandlung von Substanzgebrauchsstörungen (SUD) konzentriert, betont sein Engagement, im besten Interesse aller Aktionäre zu handeln, während es seine Strategie umsetzt. Das Unternehmen ist in über 30 Ländern tätig und beschäftigt weltweit mehr als 1.000 Mitarbeiter.
- None.
- None.
Insights
The letter from Oaktree Capital Management to Indivior's board represents a significant development in shareholder activism. Oaktree's involvement, as a major investment firm, typically signals potential strategic changes or concerns about company direction. However, without the content of Oaktree's letter being disclosed, the immediate impact remains speculative.
The board's response indicates ongoing dialogue but maintains a neutral stance, suggesting they're balancing Oaktree's proposals against broader shareholder interests. For a
The situation warrants close monitoring as activist campaigns often result in material changes to company strategy or leadership structure, potentially affecting shareholder value.
The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation. The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy.
Indivior looks forward to further engagement with Oaktree and other shareholders.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-responds-to-publication-of-a-letter-by-oaktree-capital-management-to-the-board-of-indivior-302299220.html
SOURCE Indivior PLC
FAQ
What is Indivior's response to Oaktree Capital Management's letter?
How many countries does Indivior (INDV) operate in?
What is Indivior's (INDV) main business focus?
